« Previous
Next »
Titles
- S1B(R1) addendum to S1B testing for carcinogenicity of pharmaceuticals: guidance for industry1
- Safety considerations for container labels and carton labeling design to minimize medication errors1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : report to congressional addressees1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : testimony before the Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform, House of Representatives1
- Second interim evaluation of California’s Health Homes Program (HHP)1
- Size, shape, and other physical attributes of generic tablets and capsules: guidance for industry1
- Social care 3601
- Solutions: state policies associated with higher participation1
- Some Medicare Advantage Organization denials of prior authorization requests raise concerns about beneficiary access to medically necessary care1
- Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- State Children's Health Insurance Program (SCHIP)1
- State and federal relief prevented deep backslide in health care affordability in California in 20201
- State biosimilar substitution laws could reduce consumer access and savings1
- State opportunities to improve health care coverage for child care professionals1
- State responses to FASD: effective strategies and ongoing challenges1
- State specific responses1
- State trends in employer premiums and deductibles: 2010-20201
- State use of value-based payment in nursing facilities1
- State-level trends in employer-sponsored health insurance: 2019-20211